Search

By Industry Solutions (2)
By Phase (1)
By Molecule Type (1)
By Therapeutic Area (3)
Covance Events (9)
Geography (3)
Keywords (10)

Filters

Showing results 65 - 80 of 91813 for .

Showing results 65 - 80 of 91813 for .

A Well-Developed Regulatory Strategy is Key to Increasing Your Chance of Regulatory Approval
A regulatory-science driven regulatory strategy is essential as part of today's biopharmaceutical product early development planning.
Biomarker Development for Parkinson's Disease
The implications of biomarker identification in Parkinson's Disease are enormous.
Country Selection for Your Clinical Study: There is a Method to the Madness
Choosing where to conduct a global clinical trial is a critical strategic decision that can impact a whole drug development program...
What You Don't Know about Managed Market Contracts is Hurting You
Protect your revenue with managed market contracts
Central and Eastern Europe Plays Increasingly Leading Role in Clinical Trials
Emerging Markets in Clinical Trials: Romania Delivers Pivotal Boost in Enrollment in Challenging Indication
The Role of the CRO in Frontloading Cardiovascular Safety
Cardiovascular safety remains a leading cause of drug attrition during preclinical and clinical development, accounting for discontinuation of approximately one third of marketed drugs.
Optimize the Patient Journey
We bring you leading consultative insight and keep patients connected to your product to help you maximize your product value and the patient journey.
The Individual Health Care Mandate of the Affordable Care Act: To Be or Not To Be?
Debates are gripping Capitol Hill regarding the individual mandate of the Affordable Care Act (ACA).
Examining Tau Phosphorylation as a Potential Alzheimer's Disease Biomarker
Tau proteins have an important role in stabilizing microtubules, critical structures responsible for various movements in cells.
The Challenges of Complying With the 340B Drug Pricing Program
At Covance, we know that you, the pharmaceutical manufacturer, must deal with an increasingly complex marketplace.
Reducing the Variability in Multiple Myeloma Testing
Multiple myeloma is a blood cancer that typically affects those aged 70 years and older.
How Will 340B Changes Affect You?
Manufacturers face several challenges when participating in the 340B program.
The Integrated Role of the Project Pathologist
pathologist, you may picture a scientist peering through a microscope, viewing slides and making notes about a disease state, then moving on to the next sam ...
Health Insurance Exchange Enrollment Nearing Deadline, What's Next?
The deadline to purchase health insurance through the state and federal exchanges is March 31, 2014.
Central Lab Model Provides Solutions for Oncology Trials
Testing drives drug development. From laboratory tests on patient specimens comes almost all of the clinical data needed for a new drug application. How and where those specimens are collected, transported, stored, and analyzed impacts the quality and usefulness of the data they produce.
Experience, Insights and Results = Innovative Solutions for Oncology
The gauntlet of oncology trial planning, investigation, and final approval can be daunting. Oncology is the largest, fastest-growing, and most research-intensive therapeutic area in drug development, yet the need for new agents is urgent. Plus, cancer patients are among the hardest to recruit for clinical trials.